Peer Review History: Mucormycosis and It’s Prevalence in the Patients of COVID-19

Editor(s):

(1) Dr. Syed A. A. Rizvi, Nova Southeastern University, USA.

(2) Dr. Takashi Ikeno, National Institute of Mental Health, National Center of Neurology and Psychiatry, Tokyo, Japan.

(3) Dr. Sung-Kun Kim, Northeastern State University, USA.

Reviewers:

(1) Pradeep Kumar Vyas, Holy Family Hospital And Research Centre Bandra, India.

(2) Ahasan Ullah Khan, Sylhet Agricultural University, Bangladesh.

(3) Md Abdur Razzak, Delaware Biotechnology institute, University of Delaware, U.S.A.

(4) Shimaa Mubarak Fahmy Mubarak, ELWARAK Central Hospital, Egypt.

Additional Reviewers:

(1) Diriba Alemayehu Gadisa, Ambo University, Ethiopia.

(2) G. Vithiya, Velammal Medical College Hospital and Research Institute, India.

(3) Rosy Chikkala, Promea Therapeutics Private Limited, India.

(4) Claudio Voci, Azienda Ospedaliero Universitaria di Bologna – San Orsola, Italy.

(5) Rajan Anand, Sri Satya Sai Institute of Higher Medical Sciences Prasanthigram, India.

(6) Shefali Gupta, Aiims Raebareli, India.

(6) Manuel Antonio Fernández Fernández, Instituto Andaluz de Neurología Pediátrica, Spain.

Open Peer Review Policy: Click Here

Specific Comment:

Average Peer review marks at initial stage: 8.25/10

Average Peer review marks at publication stage: 9/10

Peer Review History:


Stage 1 | Original Manuscript | File 1 | NA


Stage 2 | Peer review report_1 (Pradeep Kumar Vyas, India) | File 1 | NA


Stage 2 | Peer review report_2 (Ahasan Ullah Khan, Bangladesh) | File 1 | File 2


Stage 2 | Peer review report_3 (Md Abdur Razzak, U.S.A) | File 1 | File 2


Stage 2 | Peer review report_4 (Shimaa Mubarak Fahmy Mubarak, Egypt) | File 1 | File 2


Stage 2 | Revised_MS_v1_and_Feedback_v1 | File 1 | File 2


Stage 3 | Comment_Editor_1_v1 | File 1 | NA


Stage 3 | Comment_Editor_2_v1 | File 1 | NA


Stage 3 | Comment_Editor_3_v1 | File 1 | NA